<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01396252</url>
  </required_header>
  <id_info>
    <org_study_id>CN162-014</org_study_id>
    <nct_id>NCT01396252</nct_id>
  </id_info>
  <brief_title>Japanese Phase 1 Multiple Ascending Dose (MAD) Study</brief_title>
  <official_title>Randomized, Placebo-Controlled, Double-Blind, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-820836 in Healthy Japanese Subjects and Japanese Patients With Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to assess the safety and tolerability of multiple oral
      doses of BMS-820836 in healthy Japanese subjects and Japanese patients with depression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability based on medical review of adverse events &amp; results of vital sign measurements, electrocardiogram (ECGs), physical examinations, clinical laboratory test, suicidality evaluation &amp; Montgomery Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Day 1 through Day 33</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose pharmacokinetics parameter Maximum observed concentration (Cmax) of BMS-820836 and BMS-821007</measure>
    <time_frame>Day1 through Day 33</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose pharmacokinetics parameter Concentration at 24 h (C24) of BMS-820836 and BMS-821007</measure>
    <time_frame>Day1 through Day 33</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose pharmacokinetics parameter Time of maximum observed concentration (Tmax) of BMS-820836 and BMS-821007</measure>
    <time_frame>Day1 through Day 33</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose pharmacokinetics parameter Area under the concentration-time curve in one dosing interval (AUC(TAU)) of BMS-820836 and BMS-821007</measure>
    <time_frame>Day1 through Day 33</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose pharmacokinetics parameter Apparent total body clearance (CLT/F) of BMS-820836 and BMS-821007</measure>
    <time_frame>Day1 through Day 33</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose pharmacokinetics parameter accumulation index (AI) of BMS-820836 and BMS-821007</measure>
    <time_frame>Day1 through Day 33</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose pharmacokinetics parameter half-life (T-HALF) of BMS-820836 and BMS-821007</measure>
    <time_frame>Day1 through Day 33</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose pharmacokinetics parameter Molar ratio of metabolite to parent Cmax or AUC(TAU)</measure>
    <time_frame>Day1 through Day 33</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG parameters (heart rate, PR, QRS, QT, and QTcF intervals)</measure>
    <time_frame>Day1 through Day 33</time_frame>
    <description>QTcF intervals - QT interval corrected for heart rate according to Fridericia's formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital sign measures (heart rate and blood pressure) and the orthostatic changes</measure>
    <time_frame>Day1 through Day 33</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Arm1: BMS-820836</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Placebo matching BMS-820836</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820836</intervention_name>
    <description>Tablets, Oral, 0.5 mg, Once daily, 14 days</description>
    <arm_group_label>Arm1: BMS-820836</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820836</intervention_name>
    <description>Tablets, Oral, 1 mg, Once daily, 14 days</description>
    <arm_group_label>Arm1: BMS-820836</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820836</intervention_name>
    <description>Tablets, Oral, 2 mg, Once daily, 14 days</description>
    <arm_group_label>Arm1: BMS-820836</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching BMS-820836</intervention_name>
    <description>Tablets, Oral, 0 mg, Once daily, 14 days</description>
    <arm_group_label>Arm 2: Placebo matching BMS-820836</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820836</intervention_name>
    <description>Tablets, Oral, (initiated at 1 mg and dose escalated to the target dose of 2 mg), Once daily, 14 days</description>
    <arm_group_label>Arm1: BMS-820836</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese subjects and Japanese patients with depression (Hamilton Rating Scale
             for Depression (HAM-D) â‰¥ 14), ages 20 to 55 years.

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness.

          -  Non-compliance, or overall not suitable as determined by the investigator.

          -  History of, or current clinically significant psychiatric disorders or illnesses,
             substance abuse or dependence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taito-Ku</city>
        <state>Tokyo</state>
        <zip>1110052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2011</study_first_submitted>
  <study_first_submitted_qc>July 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2011</study_first_posted>
  <last_update_submitted>June 7, 2013</last_update_submitted>
  <last_update_submitted_qc>June 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

